- Home
- NUVL vs VVV Comparison
NUVL vs VVV Comparison
Compare NUVL & VVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- VVV
- Stock Information
- Founded
- NUVL 2017
- VVV 1866
- Country
- NUVL United States
- VVV United States
- Employees
- NUVL N/A
- VVV N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- VVV Major Chemicals
- Sector
- NUVL Health Care
- VVV Industrials
- Exchange
- NUVL Nasdaq
- VVV Nasdaq
- Market Cap
- NUVL 5.4B
- VVV 4.3B
- IPO Year
- NUVL 2021
- VVV 2016
- Fundamental
- Price
- NUVL $80.48
- VVV $39.72
- Analyst Decision
- NUVL Strong Buy
- VVV Buy
- Analyst Count
- NUVL 10
- VVV 12
- Target Price
- NUVL $119.60
- VVV $42.75
- AVG Volume (30 Days)
- NUVL 582.7K
- VVV 2.1M
- Earning Date
- NUVL 08-07-2025
- VVV 08-06-2025
- Dividend Yield
- NUVL N/A
- VVV N/A
- EPS Growth
- NUVL N/A
- VVV 56.15
- EPS
- NUVL N/A
- VVV 2.05
- Revenue
- NUVL N/A
- VVV $1,674,400,000.00
- Revenue This Year
- NUVL N/A
- VVV $6.67
- Revenue Next Year
- NUVL N/A
- VVV $15.40
- P/E Ratio
- NUVL N/A
- VVV $19.26
- Revenue Growth
- NUVL N/A
- VVV 9.56
- 52 Week Low
- NUVL $55.54
- VVV $31.02
- 52 Week High
- NUVL $113.51
- VVV $48.27
- Technical
- Relative Strength Index (RSI)
- NUVL 59.85
- VVV 69.19
- Support Level
- NUVL $76.27
- VVV $36.41
- Resistance Level
- NUVL $80.90
- VVV $39.67
- Average True Range (ATR)
- NUVL 2.55
- VVV 0.94
- MACD
- NUVL 0.19
- VVV 0.23
- Stochastic Oscillator
- NUVL 81.61
- VVV 96.26
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.